Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera

A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this mutation in the development of this disease. We desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, Manfred, Wang, Yuxun, Aleksandrowicz, Dan, Bachman, Eric, Szewczak, Alexander A., Walker, Deborah, Xu, Lin, Bouthillette, Melaney, Childers, Kaleen M., Dolinski, Brian, Haidle, Andrew M., Kopinja, Johnny, Lee, Linda, Lim, Jongwon, Little, Kevin D., Ma, Yanhong, Mathur, Anjili, Mo, Jan-Rung, O’Hare, Erin, Otte, Ryan D., Taoka, Brandon M., Wang, Wenxian, Yin, Hong, Zabierek, Anna A., Zhang, Weisheng, Zhao, Shuxia, Zhu, Joe, Young, Jonathan R., Marshall, C. Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356383/
https://www.ncbi.nlm.nih.gov/pubmed/22623993
http://dx.doi.org/10.1371/journal.pone.0037207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356383/
https://www.ncbi.nlm.nih.gov/pubmed/22623993
http://dx.doi.org/10.1371/journal.pone.0037207

Ejemplares similares